BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Brezosiran readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Brezosiran\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06585449-11299@assetmemo.bio
DTSTAMP:20261121T005402Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:Brezosiran: Phase 1 readout est. (NCT06585449)
DESCRIPTION:Brezosiran\, phase 1\, Huntington's Disease.\nStudy: A Study to
  Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease\nEstimated
  primary completion: 5 July 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/brezosiran#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06585449
URL:https://assetmemo.bio/drug/brezosiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
